Antibody
Engineering
Start your project
Antibody Design & Engineering for Your Discovery and Development Needs
MImAbs combines cutting-edge protein engineering with advanced analytical technologies to optimize the developability and manufacturability of your candidates. Our expertise helps de-risk your program and accelerate the path of your therapeutic antibodies programs from discovery to the clinic.
Making the right Antibody format for every application
Custom antibody formats
Engage multiple targets, modulate immune effector functions or enhance potency with ADC: we have the format your need.
Optimize your candidate
Humanize and minimize sequence liabilities without compromising affinity, specificity or functionality.
Accelerate early biologics development
Increase chances of success and fast-track your therapeutic antibody to the clinic.
Smarter Design for Faster Therapies
More than 60 recombinant formats
Access our Fc format bank or create custom antibody formats tailored to your needs.
Expert mAb Optimization
MImAbs applies advanced protein engineering and analytics to preserve mAb affinity, function, and enhance developability.
Custom integrated project solutions
From design to functional testing, we create and evaluate optimized variants to quickly deliver the best candidate and antibody format
Comprehensive Quality Controls
Our comprehensive quality checks guarantee that every product matches your exact needs.
Minimize Immunogenicity — Maximize Therapeutic Potential
To ensure safety and efficacy for the patients, rodent-derived antibodies must be humanized to reduce the risk of immune response against the therapeutic antibody. At MImAbs, we apply a robust CDR-grafting strategy, combining bioinformatics precision with structural insights to deliver clinically relevant antibody candidates.
Our 3-Step Humanization Process
We identify the closest human immunoglobulin germline sequences using IMGT and IGBLAST tools to define the most compatible frameworks for both VH and VL regions.
Complementarity-Determining Regions (CDRs) from the original antibody are mapped using Kabat and IMGT nomenclatures, then grafted into the selected human frameworks.
Key rodent residues are reintroduced to restore structure and specificity, manufacturability, key biophysical parameters and perfect VH/VL pairing. A panel of at least 16 humanized variants is generated.
▶ Humanized antibodies ready for downstream testing.
Enhance Developability and Manufacturability
Antibody sequences can be analyzed early to select hits with low developability risks, or during lead optimization to detect and fix liabilities ensuring manufacturable, safe, and effective therapeutic antibodies
Our 3-Step Process
For each antibody, the Fv region is modelized based on sequence homology using MOE software. The model relies on an experimental 3D structure with the highest sequence identity, providing a reliable structural framework.
Sequence liabilities are assessed by combining TAP-type (Therapeutic Antibody Profiler) developability parameters with observed N-glycosylation, deamidation, and aspartate isomerization, along with cysteine unpairing, oxidation of tryptophan and methionine, and further deamidation/isomerization events, providing a comprehensive evaluation of potential risks.
During early development, CDR analysis helps identify the most promising candidates. Applied at the lead stage, full VH/VL liability assessment an antibody engineering can enhance manufacturability and de-risk developability through targeted engineering. In that case a panel of optimized variants is systematically generated and all key functions of the lead candidate are verified.
▶ Low-liability antibodies or developability-optimized lead variants, streamlining progression toward clinical application.
We can provide custom antibody design & engineering to address every challenge
Let’s discuss your project
We can provide custom antibody design & engineering to address every challenge.
Contact an expert